Pitavastatin counteracts venetoclax resistance mechanisms including TP53 mutation in acute myeloid leukemia.
The B-cell lymphoma 2 inhibitor venetoclax has therapeutic activity in several hematological malignancies. These results provide a mechanistic rationale for clinical trials adding pitavastatin to AML regimens to prevent or overcome venetoclax resistance with TP53 mutations and other high-risk features.
The B-cell lymphoma 2 inhibitor venetoclax has therapeutic activity in several hematological malignancies. These results provide a mechanistic rationale for clinical trials adding pitavastatin to AML regimens to prevent or overcome venetoclax resistance with TP53 mutations and other high-risk features.
What the study was
- Study design
- Observational or experimental study
- Population
- Human participants; details are provided in the abstract.
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Blood neoplasia
Why it surfaced
Retained as a 8/10 high-priority candidate for Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma); PubMed metadata and abstract were assessed conservatively.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.